Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etoposide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | TOP2B known ✓ | Q02880 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | GAA | P10253 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | NCOA1 | Q15788 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etoposide SCHEMBL13439889 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL12308309 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL16568315 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL13114424 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL23064754 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL14401267 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL24482748 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL22594950 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL20598257 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL15263010 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | TOP2A 602/4885TOP2B 1005/4885CYP3A4 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.